Crossmark

National survey of percutaneous coronary intervention during the COVID-19 pandemic in Japan: second report of the Japanese Association of Cardiovascular Intervention and Therapeutics

Crossref DOI link: https://doi.org/10.1007/s12928-021-00776-5

Published Online: 2021-04-17

Published Print: 2022-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ishii, Hideki https://orcid.org/0000-0003-4348-0123
Amano, Tetsuya

Kohsaka, Shun

Morino, Yoshihiro

Yokoi, Hiroyoshi

Ikari, Yuji
License Information

Text and Data Mining valid from 2021-04-17

Version of Record valid from 2021-04-17
More Information

Article History

Received: 7 April 2021

Accepted: 9 April 2021

First Online: 17 April 2021

Declarations

:

: Hideki Ishii received lecture fees from Astellas Pharma, AstraZeneca, Bayer Pharmaceutical Co.Ltd., Chugai Pharma Inc., Daiichi-Sankyo, and MSD K. K. Tetsuya Amano received lecture fees from Astellas Pharma, AstraZeneca, Bayer, Daiichi Sankyo, and Bristol-Myers Squibb. Shun Kohsaka received investigator-initiated grant funding from Bayer and Daiichi Sankyo and received lecture fees from Bristol-Myers Squibb. Yoshihiro Morino received research grants and lecture fees from Boston Scientific Corporation, Terumo, Baier, Japan lifeline, and Daiichi-Sankyo, and received lecture fees from Kowa pharmaceutical and Amgen. Hiroyoshi Yokoi received lecture fees from Abbott Vascular Japan Co., Ltd., Amgen Astellas BioPharma, Astellas Pharma, Abbott Vascular Japan Co., Ltd., Bayer Pharmaceutical Co.Ltd., Boston Scientific Corporation, Daiichi Sankyo, HeartFlow Japan G.K., Otsuka Pharmaceutical Co., Ltd., Sanofi K.K., Takeda Pharmaceutical Company, and Terumo Co., Ltd. Yuji Ikari received research grant from Boston Scientific and Bayer.

: This study was granted an exemption from requiring ethics approval by CVIT committee.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below